Driving growth through end-to-end innovation

17 November 2021 ET
18 November 2021 JST
IMPORTANT NOTICE
For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this presentation. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This presentation is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements
This presentation and any materials distributed in connection with this presentation may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this presentation or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this presentation may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Certain Non-IFRS Financial Measures
This presentation includes discussions of “Underlying Revenue Growth,” which is a financial measures not presented in accordance with International Financial Reporting Standards (“IFRS”). Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures. Underlying Revenue Growth excludes certain items which are included in, or are calculated differently from, revenue, which is the most closely comparable measure presented in accordance with IFRS. By including this non-IFRS measure, management intends to provide investors with additional information to further analyze Takeda’s performance, core results and underlying trends. Takeda’s non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definition of underlying growth, which is on slide 53.

Medical information
This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
Welcome & Introduction

Julie Kim
President, Plasma-Derived Therapies
Our dedicated business unit is transforming the lives of patients

- Set ambitious long-term strategy to accelerate growth
- Committed to transform plasma operations and capabilities
- Set goal to increase plasma donations and capacity by >65% by end of FY2023*

*Versus FY2018 baseline
Our dedicated business unit is transforming the lives of patients

Executing successfully against long-term strategy
  • Grew IG and total PDT portfolio underlying revenue* by 16% and 6%, respectively, in FY2020

Accelerating growth through transformation:
  • Enhanced donor experience through data, digital and cloud technology

On track to reach goal of increasing donations and capacity by >65% by end of FY2023**

ON TRACK to meet our FY2021 guidance of mid-single digit growth* for PDT

*See slide 53 for the definition of Underlying Revenue Growth
**Versus FY2018 baseline
Source: Takeda internal data
While the plasma market may be unique, there are significant opportunities for growth.

**IMPORTANT NUANCES**

1. Supply dependent on donation
2. Capital intensive and complex production process
3. Plasma economics
4. Historically low innovation

...AND COMPELLING OPPORTUNITIES FOR GROWTH

1. Products have lifecycles spanning decades
2. Indication and geographic expansion
3. Products not subject to usual patent cliffs
4. Probability of success for R&D is relatively high
5. Market demand continues to grow steadily
Headwinds have intensified... and created significant opportunities to accelerate change

- Significant **declines in donation**; supply uncertainty
- **Increase in costs** to mitigate for declines
- Exposed **systemic vulnerabilities**
- Potential **disruptive therapies** (e.g., anti-FcRns)

- **Increased public attention** on plasma
- **Openness to policy** and regulatory dialogue
- Acceleration of **disruptive digital programs**
- Greater **industry collaboration**
Long-term market growth potential remains strong despite potential impact of investigational treatments in select indications

Worldwide demand for plasma-derived therapies is expected to continue to increase each year

Global plasma market ($B), 2015-23

Approximate Global IG Use by Indication & Specialty (2019)

Long-term market growth potential remains strong despite potential impact of investigational treatments in select indications.

Long-term market growth potential remains strong despite potential impact of investigational treatments in select indications

Worldwide demand for plasma-derived therapies is expected to continue to increase each year

Global plasma market ($B), 2015-23

Potential impact is limited to specific disease areas accounting for < 10% of IG use

Long-term market growth potential remains strong despite potential impact of investigational treatments in select indications

**Potential partial impact in CIDP – heterogeneity of disease area means IG still has key role**

- **CIDP** 22.5%
- **RAID** 32.2%
- **Immunodeficiency** 44.4%
- **MG** 4.7%
- **MMN** 4.6%
- **Kawasaki** 0.4%
- **PID** 27.1%
- **SID** 17%
- **ITP** 5.1%
- **IIM...** 3.2%
- **Severe infection** 0.4%
- **All Others** 15%

Long-term market growth potential remains strong despite potential impact of investigational treatments in select indications

Our performance shows we are on track to meet our goals – even in the face of unexpected and challenging circumstances

**DONORS**

- Plasma Sourcing
  - >70 new centers since FY2018
  - Increased and engaged donor base
  - Minimized pandemic-related donation declines to -11% in FY2020
  - Consistently surpassing pre-pandemic donation volumes

**Manufacturing**

- ~60% of CapEx investments on strategic supply capacity
- Optimized processes and productivity
- +3% IG process efficiency increase from FY2018 - present
- Maintained reliable supply

**Portfolio**

- Grew last liter portfolio
- 21% underlying SCIG revenue growth* in FY2020
- Focus on first liter portfolio
- Pipeline and portfolio progression

---

*See page 53 for the definition of Underlying Revenue Growth
Business Strategy Through the Eyes of the Patient

Dana Mendenhall
Head of Plasma-Derived Therapies
Strategy and Marketing

Better Health, Brighter Future
Patients are at the core of our business strategy and purpose-led growth
Our strategy addresses the needs of patients today and in the future

**PDT Ambition**
Transform the lives of patients through innovation and sustainability from plasma donation to delivery of medicines

- **A** Last Liter product growth
- **B** First Liter product growth
- **C** Operational excellence
- **D** Disruptive manufacturing/collection technologies
- **E** New geographies and partnerships
- **F** Transformative R&D

Optimize existing business

Guided by Takeda-ism and PTRB
We are driving last liter growth with our broad and differentiated range of IG therapies, offering more personalized care options

**DIFFERENTIATOR**

<table>
<thead>
<tr>
<th>Gammagard S/D</th>
<th>POTENTIAL GROWTH DRIVERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Lowest IgA content IVIG; only IG for hypersensitivity to IgA</td>
<td>• Launch TAK-880, second generation Gammagard S/D</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Kiovig</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Foundational IVIG brand</td>
<td>• MMN and CIDP indications</td>
</tr>
<tr>
<td>• Most utilized IG in the US over last 15 years*</td>
<td>• Targeted geographic expansion</td>
</tr>
<tr>
<td>• First approved treatment for MMN</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cuvitru</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• The 20% SCIG with proven tolerability profile; best-in-class patient experience</td>
<td>• Further PID growth</td>
</tr>
<tr>
<td></td>
<td>• Targeted geographic expansion</td>
</tr>
<tr>
<td></td>
<td>• Focus on pediatrics/young adults</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HyQvia</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Only once-a-month facilitated-SCIG with benefits of IVIG &amp; SCIG</td>
<td>• PID pediatric indication in US</td>
</tr>
<tr>
<td>• Hospital or home administration</td>
<td>• MMN and CIDP indications in US and EU</td>
</tr>
<tr>
<td>• Broadest SID label for SCIG in EU</td>
<td>• SID indication in EU and other geographies</td>
</tr>
</tbody>
</table>

**PORTFOLIO GROWTH**

- Integrated care solutions to shorten time to diagnosis and transform the patient experience
- Indication expansion to address needs of different patient groups
- Geographic expansion in target markets to improve patient access

---

*Based on aggregate analysis

**On an underlying revenue basis, please see page 53 for the definition of Underlying Revenue Growth

Source: MRB IG forecast to 2027
We are leading the charge for changes in the plasma ecosystem that will improve access to plasma and enable us to transform more lives.
Reaching More Patients through a Differentiated Donor Experience

Hema Tallman
Head of Global BioLife
BioLife is focused on excelling across the entire donation journey to meet the growing needs of patients.
We are reaching more donors in more places and helping more patients by rapidly and responsibly expanding our global footprint.

Meeting long-term growth demand while setting an example for the industry.

**Rapid Global Footprint Expansion**
Plan to have >200 centers globally by end of FY2021, having already added ~70 to our network since FY2018.

**Unlocking New States**
Centers in 35 US States and working with several state regulators to source more plasma.

**Commitment to Planet**
All new BioLife US Centers will be all-electric. Zero-waste to landfill by 2030 across all BioLife operations.
We are innovating at every stage of the donor journey to offer an exceptional and differentiated experience so more people choose to donate.

We've increased our donor base across the network by 21% since FY2019.
We are optimizing processes to save time and costs, ultimately enabling our teams to bring therapies to patients more quickly.

**Significant efficiency improvements across end-to-end supply chain**

**Inventory Acceleration**
Improvments made to move plasma more quickly from donation centers and warehouses.

**Routing Improvements**
Reduced shipment lead times following changes to logistics carrier routing.

**Streamlining Processes**
Improved import documentation and hold times.
From as early as Q1 FY2021, we have consistently surpassed pre-pandemic donation volumes.

SUCCESSFULLY NAVIGATED each new hurdle presented by the pandemic... and have been fast to recover.

H1 FY2021 growth is 27%
Growth in donations has come from both established and new centers.

**DONATION VOLUME GROWTH BY DRIVER | H1 FY2021**

*New center growth is defined as the volume contribution associated with the opening of 28 centers between H1 FY20 and H1 FY21*
Our continued growth is driven by expansion, transformation and optimization, underpinned by a focus on people, patient and planet.

**BUSINESS CONTINUITY**
- Centers remained operational in spite of COVID-19 or severe weather

**EMPLOYEE ENGAGEMENT AND RETENTION**
- Met recruitment target
- Staff turnover significantly lower than industry average
- Productivity levels maintained

**DATA AND DIGITAL APPROACH TO ATTRACT AND RETAIN DONORS**
- Rapid targeted engagement and enhanced safe and congenial donation experience

**OPERATIONAL EFFICIENCIES**
- Cost savings and faster decision-making, processing and distribution, with smaller carbon footprint

**WHAT**
- All new centers opened as planned
- Dedicated Critical Event Response and Volume Recovery teams
- Exceptional safety measures – screening and center layout redesign

**HOW**
- Increased internal communication
- Rapid training and deployment of new protocols
- Increased recognition

- Cloud and data-driven investments captured dynamic market & donor insights, enabling fast response
- Appointment-based scheduling
- Implementation of personalized and digitalized end-to-end experience
- Donor outreach customized to broad donor base and diverse markets

- All centers migrated to cloud
- Acceleration of inventory
- Routing improvements
- Streamlined processes
Transforming Manufacturing to Enable Sustainable Supply

Adrian Murphy
Head of Plasma Operating Unit, Global Manufacturing & Supply
We are stewards of plasma from donor to patient to ensure high-quality production of safe and efficacious therapies.

Complex, capital-intensive process takes 7-12 months.
Our world-class operations deliver consistently high-quality plasma medicines for patients globally

8 STRATEGIC LOCATIONS
plus four strategic partners, providing a robust and uninterrupted supply chain

INNOVATION MINDSET
digitalization and drive for excellence accelerating supply to patients

CONTINUALLY INVESTING
in existing state-of-the-art facilities that meet the highest quality standards

CONTINUED CAPACITY EXPANSION
increased production of our portfolio of >20 therapies to meet market growth while driving efficiencies
We continue to grow capacity at each of our facilities to enable more and more patients to have continuity of care.

**Tech transfer FDA Approval for human hyaluronidase (PH20), ensuring HyQvia supply**

**New Glassia manufacturing facility to serve more patients with Alpha-1 Antitrypsin Deficiency**

**Integration of Narita, Japan manufacturing site serving patients in Japan**

**New automated filling line for Albumin for additional ~12M vials**
We’re pulling through the full value of our expansion through our Factories of the Future program

- Harnessing data & advanced analytics
- Increasing automation and use of robotics
- Integrating augmented and virtual reality
- Partnering with technology experts

- Increasing capacity > 65% FY2018-FY2023
- Continuing to increase process efficiency
- Reducing downtime
- Enhancing employee safety and experience
- Augmenting quality control
- Improving efficiencies & saving costs

Fractionation  |  Purification  |  Fill & Finish  |  Packaging & Distribution
We’re delivering results with a focus on sustainability – setting new industry standards through ambitious carbon, water and waste goals

- Vienna, Rieti and Pisa utilize 100% renewable electricity
- US sites pursuing virtual power agreement for renewable energy
- First pharmaceutical production site in Belgium to reuse 90% of its wastewater
- Covington cooling systems use wastewater vs city water
- EU sites divert 100% of waste from landfill
- Los Angeles diverts 70%

**Example: Carbon reduction in action at a plasma facility**

- Reduce water consumption by 5%*
- Carbon emission reduction by 40%**
- Waste diverted from landfill >90%

*Compared to FY2019 baseline
**Scope 1: Direct emissions from owned or controlled sources such as burning fossil fuels like natural gas or oil in plants, offices and fleets and Scope 2: Indirect greenhouse gas emissions resulting from purchased and consumed electricity, heat, and third-party steam supplied to our facilities; Compared to FY2016 baseline
Our resilience throughout the pandemic is driving fresh momentum and new thinking towards how we can best save more lives.
Driving Innovative Care Solutions for Patients

Kristina Allikmets
Head of Plasma-Derived Therapies R&D
HANNAH
How can we make living with a chronic disease easier by integrating treatment into life more seamlessly than possible today?

EDWARD
Best available care is complex and may not be successful for him. Could the proteins within plasma represent an opportunity to effectively treat him in ways not possible today?
R&D drives innovation across the end-to-end value chain

**DONORS**

**Plasma Sourcing**

**Manufacturing**

**Portfolio**

**Business Operations & Distribution**

**Leverage technology to enhance the donor experience**
- Early-stage device development projects

**Improve manufacturing processes and develop new formulations**
- Facilitated 20% SCIG (TAK-881)
- Aralast ultra-low volume formulation (TAK-883)

**Identify and develop novel plasma protein-based therapies**
- Biomarker development, patient stratification
- Identify new plasma proteins and fractions
- Innovative combination therapies

**Develop complete care solutions and expand patient access**
- Indication expansion, geographic expansion
- Integrated device/technology solutions to enhance patient experience
We are developing healthcare solutions to help patients live a life that feels like their own.

PLASMA-DERIVED THERAPY

Highly Differentiated and Evolving Portfolio of >20 Therapies

PDT + DEVICE + ACCESS

Innovative Devices to Enhance Delivery

CONNECTED CARE PLATFORM

Targeted Programs for Integrated Care Solutions
Our pipeline and broad portfolio of therapies brings our strategy to life.

<table>
<thead>
<tr>
<th>NEAR-TERM</th>
<th>LONG-TERM</th>
<th>PLATFORMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAK-771 HYQVIA (Halozyme) MMN: EU</td>
<td>TAK-330 PROTHROMPLEX TOTAL New Indication: US</td>
<td>PLASMA PROTEOMICS for BIOMARKERS and NEW DRUG DISCOVERY</td>
</tr>
<tr>
<td>TAK-664 CUVITRU PID, SID: Japan</td>
<td>TAK-880 Facilitated 20% SCIG (Halozyme) Early-stage Device Development Project</td>
<td>PHARMACEUTICAL SCIENCES</td>
</tr>
<tr>
<td>TAK-666 FEIBA Volume Reduction</td>
<td>TAK-881</td>
<td>INTEGRATED CARE SOLUTIONS</td>
</tr>
<tr>
<td>TAK-883 ARALAST A1ATD: EU</td>
<td>ID: Japan</td>
<td>PLASMA-DRUG COMBINATIONS</td>
</tr>
<tr>
<td>TAK-339 GAMMAGARD LIQUID CIDP: US</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAK-880 Low IgA-IVIG PID: US</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAK-771 HYQVIA (Halozyme) CIDP: US &amp; EU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAK-771 HYQVIA HyHub Duo (Flextronics); US &amp; EU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAK-662 CEPROTIN Label Expansion: EU</td>
<td>TAK-771 HYQVIA (Halozyme) CIDP: US &amp; EU</td>
<td></td>
</tr>
<tr>
<td>TAK-662 CEPROTIN SCPCD: JP</td>
<td>TAK-771 HYQVIA (Halozyme) CIDP: US &amp; EU</td>
<td></td>
</tr>
<tr>
<td>TAK-883 ARALAST Ultra-low Volume Formulation</td>
<td>TAK-771 HYQVIA (Halozyme) PID, SID: Japan</td>
<td></td>
</tr>
<tr>
<td>TAK-883 ARALAST New Indication</td>
<td>TAK-771 HYQVIA (Halozyme) CIDP, MMN: Japan</td>
<td></td>
</tr>
<tr>
<td>TAK-883 ARALAST: EU</td>
<td>TAK-883</td>
<td></td>
</tr>
<tr>
<td>TAK-882 ARALAST: JP</td>
<td>TAK-883</td>
<td></td>
</tr>
<tr>
<td>TAK-881</td>
<td>TAK-883</td>
<td></td>
</tr>
</tbody>
</table>

**Abilities:**
- A1ATD= Alpha-1 Antitrypsin Deficiency
- CIDP= Chronic Inflammatory Demyelinating Polyneuropathy
- EU= Europe
- GI= gastrointestinal
- Ig= immunoglobulin
- MMN= Multifocal Motor Neuropathy
- NEC= necrotizing enterocolitis
- PID= Primary Immunodeficiency
- POC= proof of concept
- SC= subcutaneous
- SCPCD= Severe Congenital Protein C Deficiency
- SCIG= subcutaneously administered immunoglobulin
- SID= Secondary Immunodeficiency
- US= United States

**Note:** Relative timing of target approvals are represented for the items depicted and are subject to change; Near-Term represents target approvals through the end of FY2024 whereas Long-Term represents target approvals thereafter, in FY2025 and beyond. Forward-looking representation only; some activities will require FDA pre-IND consultation and future acceptance of an IND, and all items shown are subject to regulatory approvals. Table only shows selected R&D milestones and is not comprehensive. All timelines are approximate estimates as of November 17, 2021 and are subject to change.
We are committed to serving patients through geographic and indication expansions, while maximizing the potential of our broad portfolio.

**DRIVING GROWTH THROUGH LIFE CYCLE MANAGEMENT***

- Broad SID label for TAK-771 in EU (achieved Sep-2020)
- Completed enrollment in TAK-771 CIDP study (readout H2 FY2021)
- Filing TAK-771 Pediatrics in US planned for H2 FY2021
- Submission for TAK-771 HyHub AVA planned for US and EU in H2 FY2021
- Japan expansion for IG portfolio & TAK-662 (Pivotal studies initiating in H2 FY2021)
- TAK-330 DOAC reversal indication (Ph3 to start in H2 FY2021)
- Feiba STAR study near completion (TAK-666)

**EXPANDING REACH THROUGH NOVEL THERAPIES**

- TAK-881
  - First-in-human study initiated in FY2021 (FSI achieved Oct-2021)
- TAK-882
  - Non-clinical study readouts in FY2021

---

*All timelines are approximate estimates as of November 17, 2021 and are subject to change.
New modalities like anti-FcRn are expected to enter the rare autoimmune space, but are unlikely to displace the unique benefits of IG therapy.

Current CIDP treatment is guided by disease course and severity given its heterogeneous nature and lack of clear markers.

IG therapy expected to remain a first line maintenance therapy for CIDP
- Multi-faceted, broad anti-inflammatory and immunomodulatory MoA
- Effective for a broad and growing subset patients
- Well-established efficacy and safety profile (50+ years)

New targeted therapies (anti-FcRn) are not likely to fully displace IGs due to the heterogeneity of CIDP.

Anti-FcRn therapies are potentially good innovations for some CIDP patients
- Targeted mode of action, focused on one specific pathway
- Responders may be limited
- Long-term efficacy and safety not yet known
Our proteomics platform is a foundation for personalized treatment for current and future patient populations

**QUANTITATIVE PROTEOMICS PLATFORM**

With a better understanding of the physiological role of plasma proteins, these therapies can be used in new ways and in new diseases.
We are accelerating innovation through our network of 30+ strategic collaborations

Notes: Representative depiction; not exhaustive.
*Takeda supports activities of International Society on Thrombosis and Haemostasis (ISTH)
Our R&D success will unlock the full potential of plasma therapies for patients

...which continues to be enabled by:

**ADVANCING PORTFOLIO**

Well-defined, growth-driven strategy

**INNOVATING ACROSS VALUE CHAIN**

Dedicated PDT R&D budget

(>30% focused on new programs by FY2023)

**GROWING COLLABORATIVE NETWORK**

Plasma-focused independent R&D team

165+

Close proximity to Takeda Global R&D
Creating Value for Patients and Shareholders

Ramy Riad
Chief Financial Officer, Plasma-Derived Therapies
Working across the entire PDT value chain, we laid the foundation for growth and margin improvement over time

Through investments and strategy execution, we built the foundation for a respected and sustainable business focused on patients, allowing us to pursue our ambition to transform the lives of patients through innovation and sustainability.

- **+56%**
  New center growth across FY2018-H1 FY2021
  - FY18: 124
  - H1 FY21: 193

- **+40%**
  Increase in installed manufacturing capacity FY2018-present

- **100%**
  US centers migrated to DIS cloud

- **3%**
  Improvement in IG process efficiency across FY2018-present

- **>40**
  Country/product launches since inception of PDT

- **12%**
  US IG volume CAGR FY2018-2020
This foundation fuels and enables our underlying revenue growth* across the portfolio.

### PDT BU FY2020 Reported Revenue

<table>
<thead>
<tr>
<th>Product Family</th>
<th>Total</th>
<th>FY2018</th>
<th>FY2019</th>
<th>FY2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total PDT</td>
<td>509B JPY</td>
<td>$4.6B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IG Portfolio</td>
<td></td>
<td>+7%</td>
<td>+16%</td>
<td></td>
</tr>
<tr>
<td>Albumin Portfolio</td>
<td></td>
<td>+13%</td>
<td>+21%</td>
<td></td>
</tr>
<tr>
<td>Other Immunology</td>
<td></td>
<td>+6%</td>
<td>+19%</td>
<td></td>
</tr>
<tr>
<td>Other PDT Products**</td>
<td></td>
<td>+20%</td>
<td>-13%***</td>
<td></td>
</tr>
<tr>
<td>Other Immunology</td>
<td></td>
<td>+9%</td>
<td>+37%</td>
<td></td>
</tr>
<tr>
<td>Other PDT Products**</td>
<td></td>
<td>-16%</td>
<td>-8%</td>
<td></td>
</tr>
</tbody>
</table>

*See page S3 for the definition of Underlying Revenue Growth
**Other PDT Products include Feiba, Cinryze, Hemofil/Immunate/Immunine, Prothromplex, Factor VII, Plasma Collection, Other Hemophilia, Other Inhibitors, Albuminate, Bebulin, and PPSB
***FY2020 Albumin portfolio performance impacted by pause in shipments of Albumin Glass to China during H2 of FY2020

Note: Absolute values are presented on an IFRS (reported) basis. Year-on-year changes are underlying growth for FY2019 versus FY2018 pro-forma, and FY2020 versus FY2019. The FY2018 pro-forma baseline represents the sum of Takeda revenue for April 2018 to March 2019 plus Legacy Shire revenue from April 2018 through the acquisition date (January 8, 2019), both adjusted to remove the revenue from divested assets, with Legacy Shire revenue converted to JPY at the rate of 1 USD = 111 JPY (average FX rate for the previous fiscal year ended March 31, 2019) and converted from US GAAP to IFRS with no material differences.
Underpinning our IG growth is responsible plasma collection and inventory management

<table>
<thead>
<tr>
<th>IG PORTFOLIO UNDERLYING REVENUE GROWTH*</th>
<th>FY2019</th>
<th>FY2020</th>
<th>FY2021E**</th>
</tr>
</thead>
<tbody>
<tr>
<td>+7%</td>
<td>+16%</td>
<td>+5-10%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PLASMA COLLECTION GROWTH</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>+13%</td>
<td>-11%</td>
<td>+15-25%</td>
<td></td>
</tr>
</tbody>
</table>

GROWTH DRIVERS

Capacity expansion, operational efficiencies, transformation

Grounded in Takeda’s values-based priorities: Patient Trust Reputation Business

*See page 53 for the definition of Underlying Revenue Growth

**“E” represents Expected Reported Revenue in line with full-year FY2021 Revenue growth guidance
Our strategy and innovation-driven culture will drive further financial performance momentum

FY2021 performance reflective of strategy and innovation proceeding despite headwinds

**H1 FY2021 UNDERLYING REVENUE GROWTH***

<table>
<thead>
<tr>
<th>PDT BU</th>
<th>PDT IMMUNOLOGY</th>
<th>IG PORTFOLIO</th>
<th>ALBUMIN PORTFOLIO</th>
</tr>
</thead>
<tbody>
<tr>
<td>+7%</td>
<td>+11%</td>
<td>+8%</td>
<td>+35%</td>
</tr>
</tbody>
</table>

- **PDT BU**: 278.7B JPY
- **PDT IMMUNOLOGY**: 238.0B JPY
- **IG PORTFOLIO**: 181.3B JPY
- **ALBUMIN PORTFOLIO**: 41.7B JPY

**FY2021 UNDERLYING REVENUE GROWTH* GUIDANCE**

- “mid single digits” ✅
- 10-20% ✅
- 5-10% ✅
- >30% ✅

**INVESTMENT**
- Longer-term, we are focused on disruptive discovery efforts to find untapped therapeutic value in plasma
- Well-timed investments to deliver growth and maximize value for patients

**REVENUE GROWTH**
- Strong momentum expected to continue driven by last liter growth
- Effectively slowing near-term erosion of portfolio, and we expect to drive long-term growth through geo-expansion and R&D

**MARGIN IMPROVEMENT**
- Growing network will improve through ramp up and efficiencies
- Digital process improvements and operational excellence initiatives limited volume decline
- Managing donor fees and cost of goods

*See page 53 for the definition of Underlying Revenue Growth*
Closing

Julie Kim
President, Plasma-Derived Therapies
Our continued growth will be fueled by our deep understanding of patient needs and the plasma ecosystem

Harnessing data and digital to drive value

Enhancing the donor experience to attract and retain donors

Expanding capacity to improve reliability of supply

Optimizing our manufacturing network to maximize yield and drive efficiencies

Investing in transformative R&D to drive innovation

Maximizing broad portfolio to reach more patients
Our diverse team draws on a deep knowledge of plasma and has broad expertise and experience, grounded in Takeda values

Julie Kim
Head of Plasma-Derived Therapies BU

Charlie Alexander
Business Development

Kristina Allikmets
Research & Development

Linda Coplan
Human Resources

Rob de With
Europe and Canada
Tender Excellence & Payer Value

Barbara Glantschnig
Global Quality

Deborah Hibbett
Communication & Public Affairs

Ingrid Hofström
Executive Assistant

Thomas Kreil
Pathogen Safety

Remco Lemarcq
Legal

Dana Mendenhall
Strategy and Marketing

Brandon Monk
United States BU

Adrian Murphy
Global Manufacturing & Supply

Linda Peralta
Ethics & Compliance

Ramy Riad
Finance

Gabriele Ricci
IT

Hema Tallman
BioLife

Alan Walshe
Global Product and Launch Strategy

Emily Welch
Chief of Staff

Cornelia Zanetti
Growth & Emerging Markets
The Plasma-Derived Therapies business is a significant driver of Takeda’s growth

16% of Takeda’s total reported revenue in FY2020

Grounded in TAKEDA’S VALUES

Working toward SHARED GOALS

Better Health for People, Brighter Future for the World
Takeda uses the concept of Underlying Revenue Growth for internal planning and performance evaluation purposes. Underlying Revenue Growth compares two periods (fiscal quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis using a full year plan rate and exclude the impacts of divestitures. Although these are not measures defined by IFRS, Takeda believes Underlying Revenue Growth is useful to investors as it provides a consistent measure of our performance.
Glossary of Terms (In Alphabetical Order)

A1ATD  Alpha-1 Antitrypsin Deficiency
BU  Business Unit
CAGR  Compound Annual Growth Rate
CapEx  Capital Expenditure
CIDP  Chronic Inflammatory Demyelinating Polyneuropathy
DIS  Donor Information management Systems
DOAC  Direct-acting Oral Anticoagulants
EMA  European Medicines Agency
EU  European Union
FcRn  Neonatal Fc Receptor for IgG
FDA  Food and Drug Administration
FSI  First Subject In
IG  Immune globulin
IgG  Immune globulin G
IgA  Immune globulin A
IIM  Idiopathic Inflammatory Myopathies

ITP  Immune Thrombocytopenic Purpura
IVIG  Intravenous Immunoglobulin
Kawasaki  Kawasaki Disease
MG  Myasthenia Gravis
MMN  Multifocal Motor Neuropathy
MOA  Mechanism of Action
PID  Primary Immunodeficiency Disorder
PDT  Plasma-Derived Therapies
POC  Proof of Concept
RAID  Rare Autoimmune Disorder
R&D  Research and Development
SCIG  Subcutaneous IG therapy
SCPCD  Severe Congenital Protein C Deficiency
SID  Secondary Immunodeficiency Disorder
US  United States

EU  European Union

54
Driving growth through end-to-end innovation

17 November 2021 ET
18 November 2021 JST